Literature DB >> 6341335

Chemotherapy of breast cancer: current views and results.

G Bonadonna, P Valagussa.   

Abstract

The paper critically reviews major accomplishments achieved with the use of chemotherapy in the treatment of various stages of breast cancer. In spite of innumerable clinical trials, there is no evidence that in advanced breast cancer the addition of more drugs, either in concomitant, sequential or alternating fashion, to known effective combinations, was able to significantly improve the incidence and the magnitude of objective response or its median duration or survival. The addition of endocrine therapy to chemotherapy has failed so far to improve the most important end-point, i.e. total survival. Second-line chemotherapy is only moderately effective for a fairly short period of time. Thus, in women with advanced breast cancer excessive tumor cell burden and permanent drug resistance remain the major obstacles to obtaining complete remission and long-term disease free survival. In the adjuvant setting, the initial trials with combination chemotherapy have achieved consistent results, particularly in women with minimal axillary node involvement. Unless a woman has undergone a surgical breast-saving procedure, postoperative radiotherapy does not appear to play an important therapeutic role, either with or without concomitant or sequential chemotherapy. Present results would suggest that in advanced breast cancer little progress can be expected in the near future. Therefore, medical oncologists should focus on the correct application of established drug regimens, using a sequential flow of hormonal manipulations and cytotoxic chemotherapy. In high-risk groups, full dose adjuvant polydrug therapy given for a relatively short period of time appears to be at present the only means able to significantly decrease the failure rate following local regional treatment. Present consistent achievements, which appear devoid of important delay morbidity (e.g. cancerogenesis, chronic organ damage) will require further clinical research to identify more effective and less toxic treatments.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341335     DOI: 10.1016/0360-3016(83)90286-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 2.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

3.  High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.

Authors:  F Sanchiz; A Milla
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.

Authors:  A J Wilson; M Baum; D M Brinkley; J A Dossett; K McPherson; J S Patterson; R D Rubens; F G Smiddy; B A Stoll; D Richards
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

Review 5.  An assessment of current achievements in the systemic management of breast cancer.

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 6.  Current status of chemotherapy of breast cancer.

Authors:  A Coates
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

Review 7.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.

Authors:  R Metz; M Delgado; R Keiling; P Cappelaere; J P Armand; G Prevot; J L Misset; J Grimbert; G Mathe
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.

Authors:  G Francini; R Petrioli; A Aquino; S Gonnelli
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.